Rossari Biotech Q2 FY27 Revenue Hits Record ₹697.6 Cr, Up 19%; EBITDA ₹87 Cr
Rossari Biotech reported record Q2 FY27 revenue of ₹697.6 crore, up 19% YoY, and record EBITDA of ₹87.0 crore, up 20.9% YoY. H1 FY27 revenue rose 23.4% to ₹1,394.8 crore. The company approved setting up a greenfield manufacturing facility in Saudi Arabia. Net debt reduced to ₹221 crore.
The record financial performance, expansion into a new international market (Saudi Arabia), and improvements in operational efficiency (working capital, debt reduction) are significant developments that are likely to have a high impact on the company's future growth and investor outlook.
The company reported record quarterly revenue and EBITDA, along with significant year-on-year growth in key financial metrics. The announcement of a new manufacturing facility in Saudi Arabia and improvements in working capital and debt reduction further contribute to a positive sentiment.
Rossari Biotech Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026, reporting its highest-ever quarterly revenue and EBITDA.
For the second quarter of FY27, the company achieved a consolidated revenue of ₹697.6 crore, marking a 19.0% year-on-year growth. EBITDA stood at ₹87.0 crore, an increase of 20.9% year-on-year, with EBITDA margins at 12.5%, up by 20 basis points. Profit After Tax was ₹38.9 crore, which the company noted was subdued due to higher depreciation from long-term project investments. Export sales reached a record ₹216.4 crore, a 33.8% year-on-year increase. Cash flow from operations was strong at ₹131 crore, and net working capital improved to 86 days from 97 days in March 2026. Net debt declined to ₹221 crore from ₹281 crore.
In the first half of FY27, total revenue grew by 23.4% year-on-year to ₹1,394.8 crore. EBITDA increased by 19.9% year-on-year to ₹167.6 crore, with EBITDA margins at 12.0%. Profit After Tax for the half-year was ₹74.0 crore.
Key business updates include the Board's approval for leasing land by its wholly-owned subsidiary, Rossari International Limited Company, to establish a greenfield manufacturing facility in the Kingdom of Saudi Arabia. The Home, Personal Care and Performance Chemicals segment saw the completion of the Stage 1 EXCiPACT audit for its Pharma business and the commissioning of one of India’s largest EO storage facilities. The Textile Specialty Chemicals business expanded into new geographies like Peru and Indonesia and introduced new products. The Animal Health and Nutrition division launched a new range of disinfectants and introduced emulsifiers for poultry feed as a new product category.
Promoters and Executive Chairman Mr. Edward Menezes and Managing Director Mr. Sunil Chari commented that the robust growth was driven by healthy domestic business momentum and international expansion. They highlighted broad-based growth across HPPC, TSC, and AHN businesses and efforts to strengthen the balance sheet and improve cash flow generation. The KSA facility marks a key milestone in international growth, and strategic initiatives like monetizing non-core assets and rationalizing lower-margin businesses are progressing.
What to do with a filing like this
Rossari Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rossari Biotech Limited. Read the original for the full detail.